ONCOLife presents an exclusive interview with John Santini, CEO of Vergent Bioscience. In this session, we explore how ...

ONCOLife presents an exclusive interview with Dr. John Gribben, Professor at the Cancer Institute in London and Past ...

Johnson & Johnson announced the acquisition of Ambrx Biopharma for $2 billion, aiming to boost its oncology pipeline with Ambrx's innovative antibody drug conjugates.

We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the future of breast cancer screening and the role of artificial intelligence ...

ONCOLife presents an exclusive interview with Dr. Miguel-Angel Perales, Co-Chair of the CAR T Vision initiative, as he shares his expert insights on the major barriers preventing eligible patients ...

Medtronic, has received FDA approval for its PulseSelect Pulsed Field Ablation System, designed to treat patients with paroxysmal or persistent atrial fibrillation.

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

Researchers at Weill Cornell Medicine have made a breakthrough in the fight against liver cancer, by identifying a biomarker that could predict which patients are more likely to benefit from ...

ONCOLife presents an exclusive interview with Lorna Warwick, CEO of Lymphoma Coalition. In this session, we explore the critical role of patient advocacy in improving access to CAR T-cell therapy — a ...

The START Center for Cancer Research dosed the first patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent mRNA-based cancer vaccine targeting advanced solid tumors.